Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Cancer Vaccines, Adjuvants, and Delivery Systems

Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome

Chong, C., Marino, F., Pak, H., Racle, J., Daniel, R. T., Müller, M., Gfeller, D., Coukos, G., & Bassani‐Sternberg, M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir117.000383 · Cited by 188

Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy

Chowdhury, P. S., Chamoto, K., & Honjo, T. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 198

Nanocarriers based on bacterial membrane materials for cancer vaccine delivery

Zhao, X., Zhao, R., & Nie, G. (2022) · Nature Protocols · doi:10.1038/s41596-022-00713-7 · Cited by 198

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Kim, S. P., Vale, N. R., Zacharakis, N., Krishna, S., Yu, Z., Gasmi, B., Gartner, J. J., Sindiri, S., Malekzadeh, P., Deniger, D. C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0040 · Cited by 195

Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results

Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189

Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy

Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 194

A transformer-based model to predict peptide–HLA class I binding and optimize mutated peptides for vaccine design

Chu, Y., Zhang, Y., Wang, Q., Zhang, L., Wang, X., Wang, Y., Salahub, D. R., Xu, Q., Wang, J., Jiang, X. X., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00459-7 · Cited by 192

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Cui, J., Li, Y., Yang, Y., Yang, H., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J., Wang, R. L., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 208

Recent progress in Lynch syndrome and other familial colorectal cancer syndromes

Boland, P. M., Yurgelun, M. B. B., & Boland, C. R. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21448 · Cited by 191

Metabolic labeling and targeted modulation of dendritic cells

Wang, H., Sobral, M. C., Zhang, D. K. Y., Cartwright, A. N. R., Li, A. W., Dellacherie, M. O., Tringides, C. M., Koshy, S. T., Wucherpfennig, K. W., & Mooney, D. J. (2020) · Nature Materials · doi:10.1038/s41563-020-0680-1 · Cited by 190

Clinical and immunological effects of mRNA vaccines in malignant diseases

Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 186

The function and dysfunction of memory CD 8+ T cells in tumor immunity

Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, Á., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 186

Melanoma: What do all the mutations mean?

Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 197

Targeting mRNA processing as an anticancer strategy

Desterro, J. M. P., Bak‐Gordon, P., & Carmo‐Fonseca, M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0042-3 · Cited by 181

Active transcytosis and new opportunities for cancer nanomedicine

Pandit, S., Dutta, D., & Nie, S. (2020) · Nature Materials · doi:10.1038/s41563-020-0672-1 · Cited by 186

Mechanisms of immune escape in the cancer immune cycle

Tang, S., Ning, Q., Yang, L., Mo, Z., & Tang, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106700 · Cited by 195

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

Lichtenegger, F. S., Rothe, M., Schnorfeil, F. M., Deiser, K., Krupka, C., Augsberger, C., Schlüter, M., Neitz, J. S., & Subklewe, M. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00385 · Cited by 178

Emerging Nano‐/Microapproaches for Cancer Immunotherapy

Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 178

Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence

Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163

Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics

Wilhelm, M., Zolg, D. P., Graber, M., Gessulat, S., Schmidt, T., Schnatbaum, K., Schwencke-Westphal, C., Seifert, P., Krätzig, N. D. A., Zerweck, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23713-9 · Cited by 169

Inhibitors of the PD-1 Pathway in Tumor Therapy

LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 180

Chemical Strategies to Boost Cancer Vaccines

Li, W., & Li, Y. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00833 · Cited by 175

Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting

Schmidt, J., Smith, A. R., Magnin, M., Racle, J., Devlin, J. R., Bobisse, S., Cesbron, J., Bonnet, V., Carmona, S. J., Huber, F., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100194 · Cited by 181

A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction

Mei, S., Li, F., Leier, A., Marquez‐Lago, T. T., Giam, K., Croft, N. P., Akutsu, T., Smith, A. I., Li, J., Rossjohn, J., et al. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz051 · Cited by 177

Non-liver mRNA Delivery

Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173

Predicting Antigen Presentation—What Could We Learn From a Million Peptides?

Gfeller, D., & Bassani‐Sternberg, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01716 · Cited by 169

Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion

Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 171

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177

Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine

Ogino, S., Nowak, J. A., Hamada, T., Phipps, A. I., Peters, U., Milner, D. A., Giovannucci, E. L., Nishihara, R., Giannakis, M., Garrett, W. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315537 · Cited by 170

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer

Kinkead, H. L., Hopkins, A. C., Lutz, E. R., Wu, A. A., Yarchoan, M. M., Cruz, K. A., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 169

mRNA cancer vaccines: Advances, trends and challenges

He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 171

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different

Lee, C., Yelensky, R., Jooss, K. U., & Chan, T. A.-T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 164

Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer

Kong, X., Qi, Y., Wang, X., Jiang, R., Wang, J., Fang, Y., Gao, J., & Hwang, K. C. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101070 · Cited by 169

Next-generation computational tools for interrogating cancer immunity

Finotello, F., Rieder, D., Hackl, H., & Trajanoski, Z. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0166-7 · Cited by 161

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade

Mougel, A., Terme, M., & Tanchot, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00467 · Cited by 164

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00683 · Cited by 168

Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy

Wu, J., Zhao, L., Hu, H., Li, W., & Li, Y. (2019) · Medicinal Research Reviews · doi:10.1002/med.21649 · Cited by 160

Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Wang, Q., Nie, Y., Sun, S., Lin, T., Han, R.-J., Jiang, J., Li, Z., Li, J.-Q., Xiao, Y.-P., Fan, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02496-w · Cited by 161

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group

Mattos‐Arruda, L. D., Vázquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 166

Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy

Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 160

Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors

Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 158

T cell antigen discovery via signaling and antigen-presenting bifunctional receptors

Joglekar, A. V., Leonard, M. T., Jeppson, J. D., Swift, M., Li, G., Wong, S. K., Peng, S., Zaretsky, J. M., Heath, J. R., Ribas, A., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0304-8 · Cited by 151

Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function

Veatch, J. R., Lee, S. M., Shasha, C., Singhi, N., Szeto, J. L., Moshiri, A. S., Kim, T. S., Smythe, K. S., Kong, P., Fitzgibbon, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.006 · Cited by 159

Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics

Bose, R. J., Paulmurugan, R., Moon, J. J., Lee, S., & Park, H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.001 · Cited by 156

Cancer vaccines on the move

Banchereau, J., & Palucka, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.149 · Cited by 154

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy

Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 152

DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity

Wu, J., Wang, W., Zhang, J., Zhou, B., Zhao, W., Su, Z., Gu, X., Wu, J., Zhou, Z. M., & Chen, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02559 · Cited by 157

Strategies for non-viral vectors targeting organs beyond the liver

Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160

Epidemiology and biology of relapse after stem cell transplantation

Horowitz, M. M., Schreiber, H. W., Elder, A., Heidenreich, O. T., Vormoor, J. H., Toffalori, C., Vago, L., & Kröger, N. M. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0171-z · Cited by 156

Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma

Zhu, G., Su, H., Johnson, C. H., Khan, S. A., Kluger, H. M., & Lu, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.053 · Cited by 150

Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation

Liu, Z., Li, J. P., Chen, M., Wu, M., Shi, Y., Li, W., Teijaro, J. R., & Wu, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.048 · Cited by 148

Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles

Hatit, M. Z. C., Lokugamage, M. P., Dobrowolski, C. N., Paunovska, K., Ni, H., Zhao, K., Vanover, D. A., Beyersdorf, J. P., Peck, H. E., Loughrey, D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01030-y · Cited by 158

Nanovaccines for cancer immunotherapy

Zhang, Y. X., Lin, S., Wang, X., & Zhu, G. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1559 · Cited by 146

Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses

Liu, X., Feng, Z., Wang, C., Su, Q., Song, H., Zhang, C., Huang, P., Liang, X., Dong, A., Kong, D., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119649 · Cited by 148

Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy

Song, H., Yang, P., Huang, P., Zhang, C., Kong, D., & Wang, W. (2019) · Theranostics · doi:10.7150/thno.30577 · Cited by 148

The clinical promise of immunotherapy in triple-negative breast cancer

Vikas, P., Borcherding, N. C., & Zhang, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s185176 · Cited by 147

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Karasarides, M., Cogdill, A. P., Robbins, P. B., Bowden, M., Burton, E. M., Butterfield, L. H., Cesano, A., Hammer, C., Haymaker, C., Horak, C. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0586 · Cited by 154

Cancer Immunoediting in the Era of Immuno-oncology

Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 167

Challenges in neoantigen-directed therapeutics

Lybaert, L., Lefever, S., Fant, B., Smits, E., Geest, B. G. D., Breckpot, K., Dirix, L. Y., Feldman, S. A., Criekinge, W. V., Thielemans, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 147

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149

Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 145

Selecting Target Antigens for Cancer Vaccine Development

Buonaguro, L., & Tagliamonte, M. (2020) · Vaccines · doi:10.3390/vaccines8040615 · Cited by 150

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice

Haabeth, O. A. W., Blake, T. R., McKinlay, C. J., Waymouth, R. M., Wender, P. A., & Levy, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810002115 · Cited by 144

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Newey, A., Griffiths, B. L., Michaux, J., Pak, H. S., Stevenson, B. J., Woolston, A., Semiannikova, M., Spain, G., Barber, L. J., Matthews, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0769-8 · Cited by 133

Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches

Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 144

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

Hoecke, L. V., Lint, S. V., Roose, K., Parys, A. V., Vandenabeele, P., Grooten, J., Tavernier, J. H., Koker, S. D., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 146

The opposing roles of CD 4+ T cells in anti‐tumour immunity

Ahrends, T., & Borst, J. G. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 144

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139

Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis

Wen, B., Li, K., Zhang, Y., & Zhang, B. (2020) · Nature Communications · doi:10.1038/s41467-020-15456-w · Cited by 144

Artificial intelligence in early drug discovery enabling precision medicine

Boniolo, F., Dorigatti, E., Ohnmacht, A. J., Saur, D., Schubert, B., & Menden, M. P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1918096 · Cited by 147

Dendritic Cells in Cancer Immunology and Immunotherapy

Hato, L., Atienza, Á. V., Eguren‐Santamaría, I., Perez‐Gracia, J. L., Rodríguez, J., Pérez‐Larraya, J. G., Sarobe, P., Inogés, S., de Cerio, A. L. D., & Santisteban, M. (2024) · Cancers · doi:10.3390/cancers16050981 · Cited by 150

Determinants for Neoantigen Identification

García-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 139

Next-Generation Cancer Immunotherapy Targeting Glypican-3

Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., & Nakatsura, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00248 · Cited by 139

Nanotechnology approaches in the current therapy of skin cancer

Borgheti-Cardoso, L. N., Viegas, J. S. R., Silvestrini, A. V. P., Caron, A. L., Praça, F. S. G., Kravicz, M., & Bentley, M. V. L. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.005 · Cited by 141

Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle

Li, Q., Shi, Z., Zhang, F., Zeng, W., Zhu, D., & Mei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.031 · Cited by 136

Biomimetic and bioinspired nano‐platforms for cancer vaccine development

Feng, C., Tan, P., Nie, G., & Zhu, M. (2023) · Exploration · doi:10.1002/exp.20210263 · Cited by 139

RNA‐based medicine: from molecular mechanisms to therapy

Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 151

CD4+ T cells in antitumor immunity

Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 154

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

Racle, J., Guillaume, P., Schmidt, J., Michaux, J., Larabi, A., Lau, K., Perez, M. A. S., Croce, G., Genolet, R., Coukos, G., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.03.009 · Cited by 136

Immune checkpoint blockade therapy

Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 134

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Laubli, H. P., Balmelli, C., Kaufmann, L., Stanczak, M. A., Syedbasha, M., Vogt, D., Hertig, A., Müller, B. P., Gautschi, O. P., Stenner, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0353-7 · Cited by 133

The role of neoantigen in immune checkpoint blockade therapy

Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 132

The landscape of T cell antigens for cancer immunotherapy

Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 140

Recent Advances and Challenges in Cancer Immunotherapy

Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140

The immunostimulatory nature of mRNA lipid nanoparticles

Sharma, P., Hoorn, D., Aitha, A., Breier, D., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115175 · Cited by 132

Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed

Fang, L., Zhao, Z., Wang, J., Zhang, P., Ding, Y., Jiang, Y., Wang, D., & Li, Y. (2020) · Science Advances · doi:10.1126/sciadv.aba4024 · Cited by 130

The dark side of tumor-associated endothelial cells

Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 137

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri‐Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0798-2 · Cited by 128

Identification of the Cryptic HLA-I Immunopeptidome

Erhard, F., Dölken, L., Schilling, B., & Schlösser, A. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0886 · Cited by 132

Rejection of immunogenic tumor clones is limited by clonal fraction

Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K. M., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 127

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 122

Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole‐Cell Components of Tumor Tissues or Cells

Ma, L., Diao, L., Peng, Z., Jia, Y., Xie, H., Li, B., Ma, J., Zhang, M., Cheng, L., Ding, D., et al. (2021) · Advanced Materials · doi:10.1002/adma.202104849 · Cited by 124

Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives

Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 134

Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression

zhao, J., Zhang, Z., Xue, Y., Wang, G., Cheng, Y. G., Pan, Y., Zhao, S., & Hou, Y. (2018) · Theranostics · doi:10.7150/thno.29746 · Cited by 124

Immune checkpoint inhibitor combinations: Current efforts and important aspects for success

Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 121

Immunotherapy in Ovarian Cancer: Are We There Yet?

Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 126

Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response

Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 124

mRNA-Based Vaccines

Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021) · Vaccines · doi:10.3390/vaccines9040390 · Cited by 133

Personalized immunotherapy in cancer precision medicine

Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0032 · Cited by 136

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b